---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-25-000053"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:40:01.405187+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M

## Summary
- Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).
- Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.
- Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.
- Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.
- Phase 2 study of MRM-3379 for Fragile X Syndrome initiated.

## SEC filing metadata
- accession: 0001759425-25-000053
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/0001759425-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-25-000053
- JSON: https://secwatch.observer/filing/0001759425-25-000053.json
- Plain text: https://secwatch.observer/filing/0001759425-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.